Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PYRGF PyroGenesis Canada	$0.22 -1.4%	$0.31	$0.21 ▼ $0.71	$41.44M	0.83	13,104 shs	10,804 shs
RAPT Rapt Therapeutics	$11.01 -2.8%	$9.91	$5.67 ▼ $26.56	$182.04M	0.01	111,637 shs	30,993 shs
TVGN Tevogen Bio	$0.91 -2.8%	$1.11	$0.26 ▼ $3.09	$179.01M	-0.77	1.41 million shs	393,433 shs
VTYX Ventyx Biosciences	$2.56 -6.6%	$2.63	$0.78 ▼ $3.39	$182.91M	0.97	1.36 million shs	285,452 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PYRGF PyroGenesis Canada	0.00%	-13.17%	-24.29%	-31.43%	-62.95%
RAPT Rapt Therapeutics	0.00%	-3.66%	-15.03%	+14.94%	-39.32%
TVGN Tevogen Bio	0.00%	-1.25%	-11.66%	-28.52%	+61.45%
VTYX Ventyx Biosciences	0.00%	-3.18%	-13.84%	+62.13%	+21.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	4.5716 of 5 stars	4.3	3.0	0.0	4.2	1.5	1.7	1.3
TVGN Tevogen Bio	3.9696 of 5 stars	3.5	3.0	0.0	0.0	3.3	2.5	0.0
VTYX Ventyx Biosciences	2.2128 of 5 stars	3.3	3.0	0.0	0.0	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A
RAPT Rapt Therapeutics	2.57	Moderate Buy	$21.57	96.01% Upside
TVGN Tevogen Bio	3.00	Buy	$10.00	998.90% Upside
VTYX Ventyx Biosciences	2.50	Moderate Buy	$7.50	192.97% Upside

Current Analyst Ratings Breakdown

Latest PYRGF, VTYX, RAPT, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/12/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
8/8/2025	RAPT Rapt Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$51.00 ➝ $38.00
8/4/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/30/2025	RAPT Rapt Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral	$14.00
7/22/2025	RAPT Rapt Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$31.00
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
6/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/27/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PYRGF PyroGenesis Canada	$9.14M	4.53	N/A	N/A	($0.01) per share	-22.10
RAPT Rapt Therapeutics	$1.53M	118.97	N/A	N/A	$11.51 per share	0.96
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($0.09) per share	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$3.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PYRGF PyroGenesis Canada	-$21.12M	-$0.03	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A
RAPT Rapt Therapeutics	-$129.87M	-$14.17	N/A	N/A	N/A	N/A	-67.92%	-59.59%	11/11/2025 (Estimated)
TVGN Tevogen Bio	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-775.49%	11/10/2025 (Estimated)
VTYX Ventyx Biosciences	-$135.12M	-$1.68	N/A	N/A	N/A	N/A	-48.89%	-44.87%	11/6/2025 (Estimated)

Latest PYRGF, VTYX, RAPT, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	N/A	TVGN Tevogen Bio	-$0.05	-$0.03	+$0.02	-$0.03	N/A	N/A
8/7/2025	Q2 2025	RAPT Rapt Therapeutics	-$0.61	-$0.65	-$0.04	-$0.65	N/A	N/A
8/7/2025	Q2 2025	VTYX Ventyx Biosciences	-$0.45	-$0.38	+$0.07	-$0.38	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PYRGF PyroGenesis Canada	N/A	0.60	0.50
RAPT Rapt Therapeutics	N/A	13.25	13.25
TVGN Tevogen Bio	N/A	0.26	0.26
VTYX Ventyx Biosciences	N/A	19.12	19.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PYRGF PyroGenesis Canada	0.03%
RAPT Rapt Therapeutics	99.09%
TVGN Tevogen Bio	N/A
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
PYRGF PyroGenesis Canada	47.68%
RAPT Rapt Therapeutics	6.60%
TVGN Tevogen Bio	73.24%
VTYX Ventyx Biosciences	18.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PYRGF PyroGenesis Canada	90	187.53 million	96.34 million	No Data
RAPT Rapt Therapeutics	80	16.54 million	15.45 million	Optionable
TVGN Tevogen Bio	3	196.71 million	52.64 million	N/A
VTYX Ventyx Biosciences	30	71.31 million	58.35 million	Optionable

PYRGF, VTYX, RAPT, and TVGN Headlines

Recent News About These Companies

H.C. Wainwright Keeps Their Hold Rating on Ventyx Biosciences (VTYX)

August 23 at 6:20 PM | theglobeandmail.com

Piper Sandler Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)

August 23 at 6:20 PM | theglobeandmail.com

Ventyx Biosciences Reports Decreased Losses in 2025

August 15, 2025 | msn.com

3 Best Stocks to Buy Now, 8/11/2025, According to Top Analysts

August 11, 2025 | msn.com

Ventyx Biosciences (NASDAQ:VTYX) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS

August 10, 2025 | marketbeat.com

Wall Street Zen Upgrades Ventyx Biosciences (NASDAQ:VTYX) to "Hold"

August 10, 2025 | marketbeat.com

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

August 9, 2025 | finance.yahoo.com

Ventyx (VTYX) Q2 Net Loss Drops 16%

August 9, 2025 | theglobeandmail.com

Ventyx Biosciences (VTYX) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Short Interest in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Expands By 69,900.0%

August 2, 2025 | marketbeat.com

Monaco Asset Management SAM Has $1.31 Million Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

July 30, 2025 | marketbeat.com

Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?

July 22, 2025 | uk.finance.yahoo.com

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It ... - Nasdaq

July 11, 2025 | nasdaq.com

Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 10, 2025 | zacks.com

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Ventyx Biosciences (VTYX)

June 24, 2025 | theglobeandmail.com

VTYX - Ventyx Biosciences Inc News - Morningstar

June 24, 2025 | morningstar.comM

VTYX - Ventyx Biosciences Inc Financials - Morningstar

June 24, 2025 | morningstar.comM

Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m

June 17, 2025 | finance.yahoo.com

Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives

June 17, 2025 | marketwatch.com

Ventyx says Parkinson’s disease drug hit main goal in small mid-stage trial

June 17, 2025 | msn.com

Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results

June 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF, VTYX, RAPT, and TVGN Company Descriptions

PyroGenesis Canada NASDAQ:PYRGF

$0.22 0.00 (-1.38%)

As of 03:06 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

Rapt Therapeutics NASDAQ:RAPT

$11.00 -0.32 (-2.78%)

As of 03:34 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

Tevogen Bio NASDAQ:TVGN

$0.91 -0.03 (-2.82%)

As of 03:34 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

Ventyx Biosciences NASDAQ:VTYX

$2.56 -0.18 (-6.39%)

As of 03:34 PM Eastern

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time